Journal: Pain Research and Treatment

Article Title: Noninterventional Study of Transdermal Fentanyl (Fentavera) Matrix Patches in Chronic Pain Patients: Analgesic and Quality of Life Effects

doi: 10.1155/2015/198343

Figure Lengend Snippet: Conversion table for deriving the starting dosage of transdermal fentanyl from the prior daily oral dosage of opioid * (expressed as morphine oral dosage equivalence).

Article Snippet: The transdermal patch that was used throughout the study was the product Fentavera (Acino Pharma AG, Switzerland), which is a matrix patch, not a reservoir patch, and is available containing a range of amounts of fentanyl base.

Techniques:

Journal: Pain Research and Treatment

Article Title: Noninterventional Study of Transdermal Fentanyl (Fentavera) Matrix Patches in Chronic Pain Patients: Analgesic and Quality of Life Effects

doi: 10.1155/2015/198343

Figure Lengend Snippet: List of types of comedications and number of patients using them at start and during one month and 2 months of treatment with transdermal fentanyl (Fentavera) patches.

Article Snippet: The transdermal patch that was used throughout the study was the product Fentavera (Acino Pharma AG, Switzerland), which is a matrix patch, not a reservoir patch, and is available containing a range of amounts of fentanyl base.

Techniques:

Journal: Pain Research and Treatment

Article Title: Noninterventional Study of Transdermal Fentanyl (Fentavera) Matrix Patches in Chronic Pain Patients: Analgesic and Quality of Life Effects

doi: 10.1155/2015/198343

Figure Lengend Snippet: Summary of total adverse events during 2 months treatment with the transdermal fentanyl (Fentavera) patch.

Article Snippet: The transdermal patch that was used throughout the study was the product Fentavera (Acino Pharma AG, Switzerland), which is a matrix patch, not a reservoir patch, and is available containing a range of amounts of fentanyl base.

Techniques:

Journal: PLoS ONE

Article Title: A comparison of educational events for physicians and nurses in Australia sponsored by opioid manufacturers

doi: 10.1371/journal.pone.0248238

Figure Lengend Snippet: Prescription brand name opioid medicines approved by the TGA from 1996 to September 2018.

Article Snippet: Buprenorphine , Norspan , Transdermal patch , 2005/05 , 2005/12 , Chronic severe pain , Mundipharma , Y.

Techniques: Formulation, Injection, Suspension, Capsules

Journal: Drug Delivery and Translational Research

Article Title: Drug delivery to and through the skin

doi: 10.1007/s13346-024-01614-w

Figure Lengend Snippet: A Common transdermal patch designs used in marketed systems. B Demonstration of how patch area can control and determine drug input across the skin. C Close to zero-order transdermal delivery of oxybutynin over a 3-day period from a single patch. D Clear demonstration of avoidance of hepatic first-pass effect when oxybutynin is administered transdermally

Article Snippet: The solution to this shortcoming was the transdermal patch pioneered by the Alza Corporation in Palo Alto (California) that presented the drug to the skin from a delivery system, the design and area of which permitted drug input into the systemic circulation at a controlled and predictable rate (Fig. A, B) [ , , ].

Techniques: